ANTIMICROBIAL TECHNOLOGIES & DRUG DELIVERY PLATFORMS
With
Associate Professor Aaron Elbourne, RMIT University, Melbourne, Australia
RESEARCHER PROFILE
Filmed in Melbourne, Australia | January 2026
Dr Aaron Elbourne is an ARC DECRA Fellow, Jack Brockhoff ECR Fellow, and Associate Professor within the School of Science at STEM Hub. A leader in nanomaterials, soft matter science, and interface research, Aaron’s work addresses critical challenges in health and the environment.
Since becoming an independent researcher, Aaron has held continuous funding from prestigious funders, including the Australian Research Council (ARC) and the National Health and Medical Research Council (NHMRC). His research is characterised by its interdisciplinary approach, combining chemistry, materials science, and engineering. His pioneering contributions to colloid therapeutics and soft matter science have driven advancements in diagnostic tools, antimicrobial technologies, and therapeutic delivery systems. His expertise in studying nanomaterial interactions with synthetic and biological membranes has been instrumental in translating scientific discoveries into impactful applications.
Aaron is a dedicated mentor to early-career researchers (ECRs) and students, having supervised and trained numerous postgraduate and doctoral candidates. He has played a key role in securing funding for student training initiatives, including joint PhD scholarships and National Industry PhD programs, which emphasise collaboration between academia and industry.
With a strong focus on translational research, Aaron’s work bridges the gap between fundamental science and practical applications. His leadership in creating innovative technologies, fostering academic-industry partnerships, and empowering future researchers underscores his commitment to advancing science and creating a meaningful impact.
Source: Supplied
https://orcid.org/0000-0002-8562-7325
-
World-first clinical trial improves patient outcomes for kidney transplants (2023)
A world-first clinical trial conducted at the Royal Adelaide Hospital (RAH) and at hospitals across Australia and New Zealand has identified the best fluid treatment to reduce the risk of patients requiring dialysis after a kidney transplant.
Around one in three people who receive a kidney transplant suffer delayed graft function, which means the transplant doesn’t work immediately and they require dialysis.
The lead-author of the study, was Royal Adelaide Hospital Nephrologist and University of Adelaide researcher, Dr Michael Collins.
-
Food and fasting periods as medicine to prevent disease
Professor Leonie Heilbronn is based at the South Australian Health and Medical Research Institute (SAHMRI), where she leads the Obesity and Metabolism laboratory. Her research is at the interface between basic and clinical science. She is internationally recognised for her work in nutritional modulation in humans and has made major contributions to our current understanding of mechanisms underlying conditions such as insulin resistance, particularly inflammation and lipid metabolism. She has also contributed significantly to current concepts of caloric restriction (CR), intermittent fasting (IF) and time restricted eating (TRE) in humans. She has published more than 110 peer reviewed papers in scientific journals and is an Associate Editor of Obesity, and Obesity Research and Clinical Practice.
-
Stem cells used for age-related macular degeneration
Dr. Jenna Hall is a passionate and accomplished biologist with expertise in induced pluripotent stem cell (iPSC) culture, disease modelling, and high-throughput automated systems. She recently earned her PhD from the University of Melbourne, where her research focused on using iPSC-derived retinal pigment epithelium (RPE) cells to study age-related macular degeneration. Dr Hall’s technical skillset spans manual and automated cell reprogramming and differentiation, quantitative microscopy-based phenotyping, and large scale -omics analysis.
